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The fear of ?ĐŚŽŬŝŶŐ to ĚĞĂƚŚ ? is on the mind of most patients suffering from amyotrophic lateral sclerosis (ALS). So 
far, how- ever, there have been no systematic surveys concerning the dying phase in a general ALS population. We 
therefore performed a structured telephone interview with the relatives of 121 patients who died from ALS and were 
followed by the Motor Neuron Outpatient Clinic of the Department of Neurology, University of Munich, Germany. These 
data are compared with those obtained by a retrospective analysis of medical records of 50 ALS patients who were 
followed by the Wisdom Hospice, Rochester, UK. 
The data show that most ALS patients (Germany 88 %, UK 98 %) died peacefully, and no patient  ?ĐŚŽŬĞĚ to ĚĞĂƚŚ ? ? The 
symptoms most frequently reported for the last 24 hours were dyspnoea, coughing, anxiety and restlessness. 
Around half (G 55 %, UK 52%) of the patients died at home. The main palliative measures in place during the 
terminal phase were: home mechanical ventilation (G 21 %, UK 0 %), percutaneous endoscopic gastrostomy (G 27 
%, UK 14 %), morphine (G 27 %, UK 82 %) and benzodiazepines (G 32%, UK 64 %). The use of these palliative measures 
was judged to be beneficial by almost all relatives. These data support the hypothesis of a peaceful death process in 
ALS and should be communicated to patients and their relatives, at the latest after the onset 
of dyspnoea, to relieve unwarranted fears. 
 
Introduction  
How people die remains in the memories of those who live on. 
    Dame Cicely Saunders 
 
Nearly all patients suffering from amyotrophic lateral sclerosis (ALS) develop symptoms of respiratory insufficiency 
during the course of their disorder [2]. Often from the time of diagnosis and certainly in the later stages, ALS 
patients, when questioned, express fears of  ?ĐŚŽŬŝŶŐ to ĚĞĂƚŚ ? ? Clinical experience suggests that the natural course of the 
dying phase in ALS is a peaceful one. At present, however, only few data are available concerning the terminal phase of 
ALS patients, and they are restricted to ALS patients dying under the care of specialist palliative care services [16, 17]. 
We therefore performed a retrospective study on the natural history of the terminal phase in ALS in two different 
countries and clinical settings.
Subjects and methods  
 
A review of the database of the Motor Neuron Outpatient Clinic of the Department of Neurology, University of Munich, 
yielded 179 patients who had been diagnosed with probable or definite ALS according to the El Escorial criteria [7], and 
had died between January 1995 and March 1999. In 121 cases (68 %) we were able to perform a structured telephone 
interview (standardised list of questions) with the care- giver who was present at the moment of death and for all or 
most of the 24 hours preceding it (119 relatives, 2 nurses). In addition, we obtained the reports of eight nurses and three 
physicians who were present at the moment of death and confirmed the ƌĞůĂƚŝǀĞƐ ? information. The questions focused on 
the symptoms and the degree of suffering in the terminal phase (as perceived by the caregiver), the state of 
consciousness during the terminal phase, the place of death and the palliative care administered in the terminal phase 
(medication, especially opioids and benzodiazepines, nutritional aids and ventilatory support). For 88 of these patients, 
detailed medical records on the terminal phase were available to complement and confirm the care- ŐŝǀĞƌƐ ? reports. 
Similar retrospective data were available for 50 ALS patients who died between1991 ?1999 and had been followed by the 
Wisdom Hospice, Rochester, UK. This group comprises virtually all ALS patients in the Rochester area during the study 
period. The data were obtained from the ƉĂƚŝĞŶƚƐ ? charts, which included ĐĂƌĞŐŝǀĞƌƐ ? accounts as well as medical 
information recorded by hospice nurses and doctors. Statistical analyses were performed with SPSS 10.0, using the 
coefficients of correlation by Spearman and Pearson and the Mann-Whitney U- test where appropriate. 
 
Results and Discussion 
All 121 German caregivers we reached agreed to be interviewed. Fifty-eight caregivers could not be reached; 9 had 
died in the meantime, 15 had moved and the address was unknown, and in 34 cases no telephone contact could be 
established. The demographics (Table 1) show the typical sex, age and site of onset distributions of ALS patient 
populations [13, 21]. There were no significant differences in the demographic data between the German and the UK 
patient populations. The ĐĂƌĞŐŝǀĞƌƐ ?distribution shows a statistically significant preponderance of female caregivers, 
irrespective of the sex of the patient (Germany: r =  ?0.62, p < 0.001; UK: r = ?0.8, p < 0.001). We believe this to be due 
to socio-cultural influences, since taking care of the sick is usually considered a ?ĨĞŵĂůĞ ƚĂƐŬ ? in Western Europe. 
The causes of death are shown in Table 2 and, as expected, by far the most common cause of death was respiratory 
failure [8]. Interestingly, 10 sudden deaths (G 8, UK 2) were attributed to cardiac failure without further 
corroborating evidence. Autonomic function is known to be subclinically affected in a subset of ALS patients [9, 20]; 
whether these patients are more prone to this kind of ?ƐƵĚĚĞŶ ?death, is a matter for future investigation. 
A crucial question concerned the degree of suffering in the terminal phase as perceived by the caregiver. Wilkes [25] 
investigated the terminal phase and death of 262 patients with several different diagnoses. In his study the relatives 
detected pain and dyspnoea of the patients significantly more often than the hospital nurse or the general 
practitioner. Correspondingly, we assumed that interviewing the relatives could be a sensitive way to assess the 
degree of the ƉĂƚŝĞŶƚƐ ? suffering in the terminal phase. The other important question was the definition of the term 
 ?ƉĞĂĐĞĨƵů ĚĞĂƚŚ ? ? We follow Weismann [24] who defined a good or peaceful death as the type of death one would 
choose if there were a choice. 
The most important result, confirming clinical experience, is that the vast majority of ALS patients (G 88 %, UK 98 %; 
p=0.11) died peacefully and no patient  ?ĐŚŽŬĞĚ to ĚĞĂƚŚ ? (Table 3). This result corresponds closely with the 
survey from K ?ƌŝĞŶ et al. [16], in which all patients were followed by and 91 % died in a hospice institution. In the German 
patient population, only 15 patients (12%) were followed by, and only 11 (9 %) died in, a hospice institution. The 
mechanism most often hypothesised for the dying phase in ALS is that of hypercapnic coma arising from slowly 
progressing respiratory weakness and leading to a peaceful death in sleep [11]. However, it should also be noted that eight 
patients (G 7, UK 1) experienced moderate to severe suffering in the terminal phase. The symptoms reported for the 
last 24 hours are shown in Table 4. Symptoms which were not relieved satisfactorily in the terminal phase included 
cough attacks due to mucous airway congestion (n=4), restlessness and anxiety (n=3), and painful cramps (n=1). 
 
Six German patients died after a resuscitation attempt, initiated by the relatives. All six relatives considered this in 
retrospect to have been a grave mistake. This group emphasises the necessity of an early discussion of advance directives 
with ALS patients and their relatives [3, 5, 6]. The suicide rate was below 1 %, reinforcing the clinical experience that, 
although suicidal thoughts are common, suicidal acts are rare in ALS. 
 
Consideration of the state of consciousness at the time of death showed that 33 patients (27 %) were awake (i. e. had 
been alert and communicating 5 min or less be- fore death), 75 patients (62%) were asleep and 13 patients (11 %) were 
comatose, incl. the six who died after a resuscitation attempt (these data were not available for the UK patients). As shown 
in Fig. 1, a high proportion of patients (G 72%, UK 48 %) deteriorated rapidly and died within 24 hours. 
 
Around half of the patients (G 55 %, UK 52%) died at home. In Germany, 22 % died in hospital (p < 0.001 compared 
with UK 0 %), while 48 % of UK patients died in hospice (p < 0.001 compared with G 9 %; Fig. 2). These differences are most 
likely due to the fact that all UK patients were followed by a specialist palliative care team. Traditionally, a large 
proportion of ALS patients in the UK are followed by a hospice team in the late stages of the disease. In a recent 
survey, 96 % of responding British hospices reported being involved in the care of ALS patients [19], while only 40 % 
of German palliative care units accept neurological patients [12]. In addition, the availability of hospice assistance is 
significantly lower in Germany (around 6.4 hospice beds/million in- habitants, vs. around 54/million in the UK [12]). 
Nine of the German patients were intubated shortly before death due to respiratory insufficiency (p=0.048 compared 
with UK 0 %). Eight of them died on an intensive care unit; six of them were extubated prior to death at their or their 
ƌĞůĂƚŝǀĞƐ ? explicit request. The average duration of intubation was 6.3 days (range 2 ?8). These data point again to the 
urgent necessity of early discussion and institution of advance directives in ALS patients to prevent unwarranted 
medical interventions in the terminal phase [15]. 
An overview of the most important palliative measures administered during the terminal phase is given in Table 5. 
Twenty-seven percent of the German patients (UK 14 %) had a percutaneous endoscopic gastrostomy (PEG) at time of 
death, which was considered to be a beneficial palliative measure by 93 % of caregivers. Similarly, 95 % of the caregivers 
of patients on noninvasive home mechanical ventilation reported a high benefit of the procedure (but only two out of 
four using invasive ventilation). This is in agreement with previous data showing a high acceptance of noninvasive 
ventilation for ALS patients, but a higher burden of care for care- givers of tracheostomised patients [1, 15, 22]. Thick 
mucous secretions reduced the benefit of ventilation in the terminal phase for three patients (two invasive, one non-
invasive). All ventilated patients were in Germany, totalling 21 % of the Munich patient group (p=0.001 compared with 
UK). This reflects previously described differences in the availability of this treatment option between countries 
and centres [4]. 
 
The data show that a significant proportion of patients required morphine and/or benzodiazepines in the terminal 
phase. The indications for morphine were dyspnoea (G 21 %, UK 40 %) and pain (G 7 %, UK 42 %). The indications for 
benzodiazepines were anxiety due to dyspnoea (G 23 %, UK 48 %), sleep disorders (G 5 %, UK 14 %), and restlessness 
(G 4 %, UK 2%). These drugs were significantly more likely to be administered if the patient died on a palliative care 
unit (morphine: r=0.45,p < 0.001; benzodiazepines: r=0.39, p < 0.001) or was a UK patient (morphine: r=0.49, p < 
0.001; benzodiazepines: r=0.29, p < 0.001). These discrepancies reflect, in our opinion, the higher general knowledge on 
palliative treatment in the UK and correspond with published data indicating a chronic under-consumption of 
morphine in Germany [26]. Other studies have also shown that morphine can be used safely in patients with ALS [18]. 
Owing to the small number of non-peaceful deaths in our study, it is not possible to assess statistically whether the 
likelihood of a peaceful death is indeed influenced by the administration of these drugs. The care- ŐŝǀĞƌƐ ? perception of 
benefit was uniformly positive for both treatments. 
This study has several possible shortcomings. First, a selection bias cannot be excluded, since almost one third of the 
German caregivers could not be contacted. How- ever, our patient sample fully matches published epidemiological 
data for ALS with regard to age, sex, dis- ease onset and duration. Secondly, proxy assessment may be biased, 
especially if retrospective. Thirdly, com- paring data from two countries may be inappropriate if the patient groups are 
different. In our case, the lack of statistical differences between the two groups in terms of demographics argues in 
favour of the comparability of the data. 
 
The results of our survey support the hypothesis that the natural course of the terminal phase in ALS is generally, albeit 
not uniformly, a peaceful one. These data require confirmation in a prospective study. Combined, multidisciplinary 
efforts by palliative care teams and motor neuron disease clinics can allow a high proportion of the patients to die at 
home. Where this is not possible, inpatient hospices or palliative care units provide a safe and comfortable environment 
to ease the physical and psychological burden of patients and relatives during the terminal phase [16]. Whether 
palliative care measures are necessary to ensure a peaceful death can- not be decided on the basis of our data. PEG, 
noninvasive ventilation, morphine and benzodiazepines, when administered, were regarded as beneficial by almost all 
caregivers, suggesting a positive effect of these measures on the quality of life of patients and caregivers prior to the 
ƉĂƚŝĞŶƚƐ ? death. 
The proportion of peaceful deaths observed in our series compares favourably with other published data in non-ALS 
populations. The rates of peaceful deaths re- ported ranged from 47.5 % (cancer patients without sedatives [23]), 
to 78.7 % (geriatric patients [10]), up to 91,5 % (hospice patients [14]). Thus, the chances of ALS patients for a peaceful 
death appear to be above, rather than below, average. ALS patients are often anxious about the dying process from 
soon after the time of diagnosis and should be informed proactively, at the latest at onset of respiratory symptoms, 
about the natural course of the terminal phase and the good efficacy of palliative measures. This could help to 
dispel unwarranted fears of ?ĐŚŽŬŝŶŐ to ĚĞĂƚŚ ? and thus increase the quality of life of patients and families. The 
verification of this hypothesis will be the subject of a prospective study.
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Table 4 Symptoms in the last 24 hours 
Germany UK 
Dyspnoea 24 (20 %) 15 (30 %) 
Restlessness and anxiety 10 (8 %) 3 (6 %) 
Choking on saliva or mucus 9 (7 %) 0 (0 %) 
Coughing 5 (4 %) 10 (20 %) 
Diffuse pain 2 (2 %) 1 (2 %) 
 
Germany UK 
107 (88 %) 49 (98 %) died peacefully 
6 (5 %) 0 (0 %) died in moderate suffering 
1 (1 %) 1 (2 %) died in severe suffering 
6 (5 %) 0 (0 %) died after a resuscitation attempt 

























Table 5 Palliative effect of nutritional aids, ventilator support and medication in the terminal 
phase 
PEG   Ventilation  Morphinea 
Germany UK Germany  UK Germany  UK 
Benzodiazepines 
Germany UK 
Patients 33 (27 %) 7 (14 %) 25 (21 %) 0 
 
± 
33 (27 %) 41 (82 %) 39 (32 %) 32 (64 %) 
   (21 noninvasive,     
   4 invasive)     
Mean dosage (range) ± ± ± 90 mg/d (10±360) 115 mg/d n. a. n. a. 
     (8±570)   
Mean duration (range) 198 d (6±1008) 179 d 297 d (2±1695) 6 d (1±52) n. a. 120 d (1±1400) n. a. 
  (18±810)      
Beneficial according 30 (91 %) n. a. 20/21 noninvasive 30 (91 %) n. a. 33 (85 %) n. a. 
to caregivers   (95 %)     
   2/4 invasive (50 %)     
Reduced or no benefit 3 (9 %) n. a. 1/21 noninvasive 3 (9 %) n. a. 6 (15 %) n. a. 
   (5 %)     
   2/4 invasive (50 %)     
Comments 2 PEG removals  Thick mucous   Neg. side effects  
 due to infection  secretions limited   in 6 pts: drowsiness,  
   






Figure 1 Place of death. ICU, intensive care unit * p = less than 0.001 compared to UK 
 
Figure 2 Time between acute deterioration and death 
 
 
